Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 460-465

  Bennett, Charles L ^a,b   Golub, Robert M ^a   Stinson, Tammy J ^b   Aboulafia, David M ^c   Von Roenn, Jamie ^a   Bogner, Johannes ^d   Goebel, Franc D ^d   Stewart, Simon ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

AIDS; Cost effectiveness; Daunorubicin; Doxorubicin; Kaposi's sarcoma; Liposomes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRIORITY JOURNAL;

EID: 0032529420     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00007     Document Type: Article

References (22)

1. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effectiveness profiles of flutamide in prostate cancer: are they helpful to policy makers? Cancer 1996;77:1854-61.
2. Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV/AIDS at CD4-positive counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:413-420.
3. Northfelt DW. AIDS-related Kaposi's sarcoma: still a problem, still an opportunity. J Clin Oncol 1994;12:1109-1110.
4. Bigger RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 1996;10:997-1010.
5. Brenner DC. Liposomal encapsulation: making old and new drugs do new tricks. J Natl Cancer Inst 1989;81:13-15.
6. Counkell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of AIDS-related Kaposis Sarcoma. Drugs 1997;53:520-38.
7. Northfelt DW, Mortin MJ, Kaplan LD, et al. Pharmacokinetics, tumor location and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi's Sarcoma [abstract]. Proc Am Soc Clin Oncol 1993;12:51.
8. Stewart JSW, Jablonowski H, Goebel FD, et al. A randomized comparative trial of liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998;16:683-91.
9. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14: 2353-64.
10. Northfelt DW, Dezube B, Miller B, et al. Randomized comparative trial of pegylated liposomal doxorubicin (Doxil) versus doxorubicin (Adriamycin), bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma. Proc Am Soc Hematol 1995;86:382a.
11. Gill PS, Wernz J, Myers A, et al. Liposomal encapsulated daunorubicin in AIDS-related pulmonary Kaposi's sarcoma. Proc Am Soc Clin Oncol 1997;16:55a.
12. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-74.
13. Krown SE, Metroka C, Wernz J. Kaposi's Sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging. J Clin Oncol 1989;7:1201-07.
14. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-9.
15. Courkell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodnamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997;53:520-38.
16. Savage GE, Gable C, Motte K, Dixon C, Becker R. A pharmacokinetic analysis of Kaposi's sarcoma patients based on a clinical trial of ABV versus liposomal daunorubicin. Proceedings of the XIth International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
17. Bennett CL, Armitage JL, Buchner D, Gulati S. Economic analysis in phase III clinical cancer trials. Cancer Invest 1994;12:336-42.
18. Gompels MM, Hill A, Jenkins P, et al. Kaposis sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 1992;6: 1175-80.
19. Gill P, Rarick M, Bernstein-Singer M, et al. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990;13:315-19.
20. Laubenstein LJ, Krigel RL, Odajnyk CM, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984;2:1115-20.
21. Gill PS, Rarick M, McCutchan JA, et al. Systematic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
22. Gill PS, Miles SA, Mitsuyasu RT, et al. Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1994;8:1695-9.